Anti-CD3-anti-MOv18 monoclonal antibody

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD3-anti-MOv18 monoclonal antibody
Drug Alias NameOC-TROC-TR bispecific monoclonal antibody
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-CD3T lymphocytes stimulantsAnti-FOLR1
TargetsFolate receptor alphaT cell surface glycoprotein CD3
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCentocor
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCentocor
Active IndicationsN/A
Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A